Related references
Note: Only part of the references are listed.Two-Year US Pharmacovigilance Report on Brodalumab
Mark Lebwohl et al.
DERMATOLOGY AND THERAPY (2021)
Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial
Luis Puig et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1)
K. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Psoriasis: Which therapy for which patient Focus on special populations and chronic infections
Shivani B. Kaushik et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis
Guomei Xu et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2019)
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
Mark G. Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?
Mina Amin et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Share Paper
